Carol Fischer, MD
Family Medicine · Cheyenne, WYNPI 1205946589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,462, 2.5 times the $585 reported in 2019. Among family medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$901
- AbbVie$677
- Novo Nordisk$544
- GSK$352
- Amgen$342
- AstraZeneca$341
- plus $3K from 39 others
What the payments were for
- Food & beverage$6,09997%
- Education$1883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,287 in reported general payments places this provider in the 95th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 111 | $327,064 |
| JulucaDolutegravir/Rilpivirine | 74 | $258,894 |
| EliquisApixaban | 210 | $210,887 |
| FarxigaDapagliflozin Propanediol | 108 | $113,560 |
| XareltoRivaroxaban | 90 | $96,474 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 24 | $94,691 |
| JardianceEmpagliflozin | 82 | $86,658 |
| OzempicSemaglutide | 50 | $78,952 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $56,876 |
| MyrbetriqMirabegron | 68 | $54,635 |
| TrulicityDulaglutide | 45 | $52,540 |
| JanuviaSitagliptin Phosphate | 23 | $31,450 |
| MounjaroTirzepatide | 28 | $30,386 |
| RybelsusSemaglutide | 31 | $27,867 |
| LinzessLinaclotide | 33 | $27,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca | $901 | $585,958185 claims |
| PfizerEliquis | $148 | $210,887210 claims |
| AstraZenecaFarxiga | $341 | $113,560108 claims |
| Novo NordiskOzempic, Rybelsus | $544 | $106,81981 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $267 | $98,92796 claims |
| Johnson & JohnsonXarelto | $152 | $96,47490 claims |
| GileadBiktarvy | $119 | $94,69124 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $352 | $86,527116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $152 | $82,92673 claims |
| Astellas Pharma US IncMyrbetriq | $262 | $54,63568 claims |
| AbbVieLinzess, Synthroid | $677 | $33,981131 claims |
| MerckJanuvia | $287 | $31,45023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Cheyenne
- Jonathon MedinaCheyenne$6K
- Douglas EdgrenCheyenne$5K
- Nancy BergquistCheyenne$3K
- Amy HarnishCheyenne$2K
- Joseph DobsonCheyenne$2K
- Gregory StampfliCheyenne$2K
- Samuel HartCheyenne$2K
- Aaron FreemanCheyenne$2K
- Patrick YostCheyenne$1K
- Kimberly BroomfieldCheyenne$971
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.